Help - Search - Members - Calendar
Full Version: Medical/Scientific Articles
Hepatitis C Association ~VOICES~ > Message Boards > Medical/Scientific Articles
Pages: 1, 2, 3
  1. Pinned: Viral Hepatitis Bill Action Alert (0 replies)
  2. Pinned: Product Development (0 replies)
  3. Pinned: Hepatits C Acronyms (0 replies)
  4. Hope Against Hepatitis C (1 reply)
  5. Depression Overlooked In Patients (0 replies)
  6. Infergen Combo For Re-treatment (0 replies)
  7. When To Extend Treatment (0 replies)
  8. Viral Hepatitis: The Secret Epidemic (0 replies)
  9. Fda Approves Rapid Test (0 replies)
  10. Beta Blockers Alone More Effective For First Variceal Bleeding (0 replies)
  11. Poor Compliance With Cirrhosis Surveillance Recommendations (0 replies)
  12. Minority Organ Donations Up (0 replies)
  13. Treatment For Compensated Cirrhotic Patients (0 replies)
  14. Orlistat (xenical) & Severe Liver Injury (0 replies)
  15. Telaprevir And The Hardest Cases Of Hep C (0 replies)
  16. Vit A Boosts Treatment Response (0 replies)
  17. Telaprevir Resistance (0 replies)
  18. Impact Of Treatment On Hcc (0 replies)
  19. Telaprevir For Previously Treated Chronic Hcv Infection (0 replies)
  20. Peg In Latinos Vs Non-latinos (0 replies)
  21. Peg & Children (0 replies)
  22. Seminal Fluid & Ribavirin (0 replies)
  23. Mortality (0 replies)
  24. Which Peg Is Better? (0 replies)
  25. Vitamin A From D D W (0 replies)
  26. Fda Considers Expanded Use Of Drugs (0 replies)
  27. Liver Transplant & Cellular Aging (0 replies)
  28. Modest" Results With Nitazoxanide (0 replies)
  29. Peginterferon Alfa-2b And Ribavirin For Liver Transplant Patients (0 replies)
  30. Warning On Propylthiouracil For Hyper-thyroidism (0 replies)
  31. Warehousing Patients/new Drugs (0 replies)
  32. Renal Cell Carcinoma (0 replies)
  33. Telaprevir Raises Response Rates In Hepatitis C (0 replies)
  34. Donor Kidneys Wasted (0 replies)
  35. Anti-fungal Medication Risks (0 replies)
  36. Virus & Osteoporosis (0 replies)
  37. Ribavirin - Early Response (0 replies)
  38. Alt & Ast - What Is Really Normal? (0 replies)
  39. Lambda Interferon Trial (0 replies)
  40. High Sustained Virologic Response Rates In Children (0 replies)
  41. Importance Of Vitamin D (0 replies)
  42. Rapid Response To Treatment (0 replies)
  43. Metformin And Treatment Response (0 replies)
  44. Which Peg? (0 replies)
  45. Safety In Treatment (0 replies)
  46. Unlikely To Treat Hep C? (0 replies)
  47. Silent Epidemic (0 replies)
  48. Sprint 1 Study, Phase 2, Boceprevir (0 replies)
  49. Telaprevir (0 replies)
  50. Narlaprevir (sch 900518) (0 replies)
  51. Hcv Response Linked Strongly To Gene Variant (0 replies)
  52. Direct Antivirals Can Beat Hcv Without Interferon (0 replies)
  53. Lambda Interferon (0 replies)
  54. Most Who Od On Prescription Opiates Took Methadone (0 replies)
  55. More On Coffee (0 replies)
  56. Reduction In Ribavirin Increases Risk Of Relapse (0 replies)
  57. Depression (0 replies)
  58. Public Health & Hep C (0 replies)
  59. Weight & Hep C (0 replies)
  60. Incidence & Risk Of Hcc (0 replies)
  61. Hepatitis C Drug Development (0 replies)
  62. Who Will Respond To Treatment? (0 replies)
  63. Coffee & Fibrosis Progression (0 replies)
  64. Treatment In Patients With Normal Enzymes (0 replies)
  65. Escalating Dose In Patients Waiting For Transplant (0 replies)
  66. Lipids & Svr (0 replies)
  67. Nurse Reuses Equipment (0 replies)
  68. Some Success For Aids Vax (0 replies)
  69. Geno 3 + Progression Of Fibrosis (0 replies)
  70. Liver Mimics (0 replies)
  71. Guidelines Help Primary Care Doctors Treat Liver Transplant Recipients (0 replies)
  72. Treatment In Prison (0 replies)
  73. Hep B Outbreak In Nj (0 replies)
  74. Guidelines For H1n1 (0 replies)
  75. Sexual Dysfunction In Men (0 replies)
  76. Bone Loss & Cirrhosis (0 replies)
  77. From Fda (0 replies)
  78. New Hope For A Cure (0 replies)
  79. Genotype 3 & Rapid Progression (0 replies)
  80. Insulin Resistance Predicts Rapid Virological Response (0 replies)
  81. Genotype 3 & Progression Of Fibrosis (0 replies)
  82. Coffee & Progression Of Hep C (0 replies)
  83. Advocates Urge Treatment For Idu's (0 replies)
  84. Biomarker Predicts Response To Treatment (0 replies)
  85. Protein & Cholesterol May Increase Risk Of Cirrhosis & Cancer (0 replies)
  86. Herbal Supplement Suspect In Hepatitis (0 replies)
  87. Weight - Related Factors In Hep C (0 replies)
  88. Lower-dose Therapy Controls Hcv (0 replies)
  89. Treatment Options Equally Effective (0 replies)
  90. Investigating Why The Immune System Fails To Control Hepatitis C (0 replies)
  91. Peg Or Peg? (0 replies)
  92. Liver Tx In Hiv Patients (0 replies)
  93. Untreated Hep C & Health-related Quality Of Life (0 replies)
  94. Orasure (0 replies)
  95. Hepatitis C Outbreak In Colorado (0 replies)
  96. Interferon & Fibrosis (0 replies)
  97. Bilirubin & Anemia (0 replies)
  98. Panel May Recommend Pulling Some Acetaminophen Drugs (0 replies)
  99. Treatment Response In Hispanics (0 replies)
  100. Liver Enzyme Elevations Late In Treatment (0 replies)
  101. Detectable Viral Load At Week 8 Predicts Relapse In Genotype 1's (0 replies)
  102. More On Telaprevir (0 replies)
  103. Hepatocellular Carcinoma & Svr (0 replies)
  104. Telaprevir (0 replies)
  105. Maintenance Peginterferon (0 replies)
  106. Alinia (0 replies)
  107. Hcc (0 replies)
  108. Genotype 3 And Response Rates (0 replies)
  109. Consensus Interferon (0 replies)
  110. Response In Hispanics (0 replies)
  111. Graves' Disease Drug Can Damage Liver (0 replies)
  112. Telaprevir Improves Hcv Clearance (0 replies)
  113. Interferon Has Long-term Histo Benefits (0 replies)
  114. Viral Load Decline At Day 2 Of Interferon-based Therapy Predicts Susta (0 replies)
  115. Blood-pressure Drug Shrinks Scars (0 replies)
  116. Svr Results Of Prove 3 (0 replies)
  117. Pollution & Liver Disease (0 replies)
  118. Report Predicts Costly Epidemic (0 replies)
  119. Reduced Dose And Duration Of Pegintron (0 replies)
  120. Ideal Study (0 replies)
  121. Statins May Cut Liver Cancer Risk In Diabetics (0 replies)
  122. Dose Adjustments (0 replies)
  123. Hypothyroidism Linked To Liver Cancer In Women (0 replies)
  124. Predicting Mortality Risk In Compensated Cirrhosis (0 replies)
  125. Cancer Preventive Effect For Statins Indicated By Study (0 replies)
  126. Patients With Resolved Hepatitis C Likely Still Contagious (0 replies)
  127. Retreatment Of Non- (0 replies)
  128. 2 Oral Antiviral Agents (0 replies)
  129. Telaprevir And Genotype 3 (0 replies)
  130. Diabetes, Obesity And Hypertension (0 replies)
  131. Treatment Improves Fibrosis (0 replies)
  132. Predicting Mortality In Cirrhotic Patients (0 replies)
  133. Predicting Mortlity Risk In Cirrhosis (0 replies)
  134. Clinical Trial Recruiting Patients With Hepatocellular Carcinoma (0 replies)
  135. Relapse Rates In Genotype 1 Depend On Weight-based Ribavirin Dosage (0 replies)
  136. Possible Contamination At 3 Veteran's Admin Hospitals (0 replies)
  137. Nj Warns Nearly 3,000 To Get Tested For Hep B (0 replies)
  138. Shorter Hcv Treatment Shows Notable Success (0 replies)
  139. Hcv Reinfection And Superinfection (0 replies)
  140. Response To Therapy In Chronic Hepatitis C Predicted By 2-day Results (0 replies)
  141. Vertex Hep C Drug Improves Cure Rate (0 replies)
  142. Progress Reported Against Gene Involved In Hepatitis C (0 replies)
  143. Liver Cancer Rate Triples, But Survival Improves (0 replies)
  144. The Role Of The Omentum In Regenerating The Liver (0 replies)
  145. Vertex Acquires Vch-222 And Vch-759 (0 replies)
  146. Elevate Study For Low Platelets (0 replies)
  147. Vitamin D Deficiency & Liver Disease (0 replies)
  148. Alinia (0 replies)
  149. Methadone For Pain (0 replies)
  150. Extending Treatment (0 replies)
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.
Invision Power Board © 2001-2010 Invision Power Services, Inc.